Shares of the kidney dialysis provider witnessed a loss of 2.97% over the previous month, trailing the performance of the Medical sector with its loss of 1.99% and the S&P 500's gain of 4.34%. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $9.62 per share and a revenue of $12.74 billion, representing changes of +13.58% and +4.97%, respectively, from the prior year. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. ...

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. The latest trading session saw DaVita HealthCare (DVA) ending at $142.16, denoting a -0.53% adjustment from its last day's close ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are ...

Denver, CO-headquartered DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease mana ...

Thus, at the moment, investing in service-oriented companies like CareCloud, Inc. (CCLD) , DaVita Inc. (DVA) , RadNet, Inc. (RDNT) , SkyWest, Inc. (SKYW) and American Express Company (AXP) seems judicious. The NMI, incidentally, had fallen into the contraction territory for the first time in April since December 2022. Any reading below the 50% mark indicates a contraction. The business activity index increased to 61.2% in May from 50.9% in April and expanded for the 48th successive month. The index has notc ...

DaVita (DVA) recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis until Aug 31, 2024.At the conclusion of the pilot phase, DaVita may extend the supply agreement with Nuwellis for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years. Price Performance Image Source: Zacks Investment Research In June 2023, DaVita and Nuwellis entered into a supply and collaboration agreement for the use of Aquadex ultrafiltrati ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. DaVita HealthCare (DVA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. DaVita HealthCare is a member of our Medical group, which includes 1044 ...

The most recent trading session ended with DaVita HealthCare (DVA) standing at $143.18, reflecting a -0.46% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.11%. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq lost 0.23%. Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in ...

MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, today announced the extension of its pilot phase under its previously announced supply and collaboration agreement with DaVita Inc. (NYSE: DVA) until August 31, 2024. This program aims to pilot Aquadex® ultrafiltration therapy for adult patients suffering from congestive heart failure and related conditions in select U. ...

"We are pleased to be able to support DVA in this transition and are excited for this next chapter with Danielle and the entire team in Portland," remarked Radiant's Founder and CEO, Bohn Crain. "We have purposefully positioned ourselves to bring value to logistics entrepreneurs like Danielle and believe that the DVA transaction is representative of a broader pipeline of opportunities available to us in the marketplace. We have a particular interest in continuing to build density in markets like Portland, w ...